Fig. 5
Optimization of patient specific ODCs. A Regression coefficients generated from search 1 of the TGMO-based screen on PDOs, describing single drug 1st order, drug-drug and single drug 2nd order drug-drug interactions (red, burgundy and pink lines, respectively) for CRC-1 B. CRC-2 and C. CRC-3 (left panels). In yellow is highlighted the most robust drug-drug interaction in each patient specific ODC. In the corresponding middle panels, activity of the patient specific ODCs, corresponding monotherapies (solid colored bars), and FOLFOXIRI (folinic acid [0.5 µM], 5-FU [10 µM], SN38 [0.1 µM] and oxaliplatin [0.5 µM], red bars) in each PDO and in CCD841 3Dcc (black stripped bars). Activity is measured by ATP levels vs. CTRL (< 0.15% DMSO). Data is presented as mean of N = 3 independent experiments, error bars represent SD. Significance is determined by one-way ANOVA (regression models, left panel) and two-way ANOVA (activity graphs, right panel) with *p < 0.05, **p < 0.01 and ***p < 0.001. In the right panels, representative images of PDO treated with their corresponding patient specific ODC. Scale bar represents 500 µm